Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Par Acquires Spectrum's Interest in Sumatriptan Injection
May 8, 2008
Par Pharmaceutical Companies, Inc. announced that it amended its agreement with Spectrum Pharmaceuticals, Inc. for $20 million in cash to increase its share of profits from the generic versions of GlaxoSmithKline's Imitrex Injection, which will be immediately accretive to 2008 earnings and provide a strong return on the Company's investment.
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing